基于冠状病毒肺炎寒湿疫毒袭肺证病证结合模型的金柴抗病毒胶囊疗效评价  

Efficacy Evaluation of Jinchai Kangbingdu Capsule Based on Coronaryvirus Pneumonia with ’Hanshi Yidu Xifei’ syndrome Model

作　　者：郭姗姗[1] 李丹 时宇静[1] 鲍岩岩[1] 赵荣华[1] 耿子涵 孙静[1] 包蕾[1] 高英杰[1] 崔晓兰[1] GUO Shan-shan;LI Dan;SHI Yu-jing;BAO Yan-yan;ZHAO Rong-hua;GENG Zi-han;SUN Jing;BAO Lei;GAO Ying-jie;CUI Xiao-lan(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China;Shineway Pharmaceutical Group Ltd.,Shijiazhuang 051400,China)

机构地区：[1]中国中医科学院中药研究所,北京100700 [2]神威药业集团有限公司,石家庄051400

出　　处：《中国实验方剂学杂志》2020年第13期1-7,共7页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：目的:在人冠状病毒肺炎寒湿疫毒袭肺证病证结合模型上,研究金柴抗病毒胶囊的治疗作用,为评价其防治冠状病毒感染提供试验依据。方法:取Balb/c小鼠48只,按体质量随机分为正常组、病毒感染组、寒湿组、寒湿疫毒袭肺证模型组、金柴抗病毒胶囊高、低剂量组(1.76,0.88 g·kg^-1·d^-1),采用寒湿刺激加人冠状病毒229E感染模拟人冠状病毒肺炎寒湿疫毒袭肺证的病证结合模型,通过观察Balb/c小鼠行为表征、肺指数、病毒载量、肺组织病理改变来评价金柴抗病毒胶囊的治疗作用;通过酶联免疫吸附测定(ELISA)检测肺组织中白细胞介素-6(IL-6),IL-10,肿瘤坏死因子-α(TNF-α),γ干扰素(IFN-γ)含量和血清中胃动素(MTL),胃泌素(GAS)含量,流式细胞术检测外周血中CD4+T细胞,CD8+T细胞,B细胞含量。结果:与寒湿疫毒袭肺证模型组比较,金柴抗病毒胶囊可增加寒湿疫毒袭肺证小鼠的活动度和反应能力,改善小鼠皮毛和大便状态,金柴抗病毒胶囊高、低剂量组可以显著降低肺指数(P<0.01),明显升高CD4+T细胞,CD8+T细胞,B细胞含量(P<0.05,P<0.01);金柴抗病毒胶囊低剂量组显著降低血清中MTL含量,显著降低肺组织中病毒载量和IL-6,IL-10,TNF-α,IFN-γ含量(P<0.01),改善肺组织病理损伤。结论:金柴抗病毒胶囊在人冠状病毒肺炎寒湿疫毒袭肺证模型上具有较好的治疗作用,其可以改善寒湿证的行为表征和胃肠道指标水平,同时减低肺指数和肺组织中病毒载量,改善肺组织病理损伤,初步探讨其机制可能与降低炎症因子含量、提升淋巴细胞数量有关。Objective: To study the therapeutic effect of Jinchai Kangbingdu capsule based on human coronavirus pneumonia with ’Hanshi Yidu Xifei’ syndrome model,in order to provide experimental basis for evaluating its effect in preventing and treating coronavirus infection. Method: The 48 Balb/c mice were randomly divided into normal group,virus infection group,cold-dampness group,cold-dampness epidemic toxin lung syndrome model group, and high and low-dose Jinchai Kangbingdu capsule groups(1. 76,0. 88 g·kg^-1·d^-1). A cold-dampness stimulation combined with human coronavirus 229 E infection was used to imitate human coronavirus pneumonia with ’Hanshi Yidu Xifei’ syndrome model. Behavioral characteristics,lung index,viral load,and lung tissue pathological changes in Balb/c mice were observed to evaluate the therapeutic effect of Jinchai Kangbingdu capsules. The contents of interleukin-6(IL-6),IL-10,tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)in lung tissue and motilin(MTL),gastrin(GAS)in serum were detected by enzyme-linked immunosorbent assay(ELISA),and the contents of CD4+T cells,CD8+T cells,and B cells in peripheral blood were detected by flow cytometry. Result: Compared with the cold-dampness epidemic toxin lung syndrome model group,Jinchai Kangbingdu capsule can increase the activity and response ability of’Hanshi Yidu Xifei’ syndrome model mice,and change the skin and stool status of mice. High and low-dose Jinchai Kangbingdu capsule groups can significantly reduce the lung index(P<0. 01),while significantly increased the content of CD4+T cells,CD8+T cells,and B cells(P<0. 05,P<0. 01). Low-dose Jinchai Kangbingdu capsule group could significantly decrease the MTL content in serum and the levels of IL-6,IL-10,TNF-α,IFN-γ in lung tissue(P<0. 01),whereas alleviate the pathological damage of lung tissue. Conclusion:Jinchai Kangbingdu capsule showed a therapeutic effect on human coronavirus pneumonia with ’Hanshi Yidu Xifei’ syndrome model,and can improve the behavioral characterization and g

关 键 词：金柴抗病毒胶囊 冠状病毒 寒湿疫毒袭肺证 炎性因子 病证结合 

分 类 号：R2-0[医药卫生—中医学] R22